Citius Oncology (CTOR) Competitors $1.16 -0.04 (-3.33%) As of 02/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends CTOR vs. TRML, MBX, ACB, TERN, FHTX, TSHA, CYRX, ANNX, CRVS, and TRVIShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Tourmaline Bio (TRML), MBX Biosciences (MBX), Aurora Cannabis (ACB), Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Taysha Gene Therapies (TSHA), Cryoport (CYRX), Annexon (ANNX), Corvus Pharmaceuticals (CRVS), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Tourmaline Bio MBX Biosciences Aurora Cannabis Terns Pharmaceuticals Foghorn Therapeutics Taysha Gene Therapies Cryoport Annexon Corvus Pharmaceuticals Trevi Therapeutics Tourmaline Bio (NASDAQ:TRML) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Which has more risk and volatility, TRML or CTOR? Tourmaline Bio has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Citius Oncology has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500. Which has preferable valuation and earnings, TRML or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$2.82-4.33Citius OncologyN/AN/A-$21.15MN/AN/A Does the MarketBeat Community believe in TRML or CTOR? Tourmaline Bio received 16 more outperform votes than Citius Oncology when rated by MarketBeat users. CompanyUnderperformOutperformTourmaline BioOutperform Votes17100.00% Underperform VotesNo VotesCitius OncologyOutperform Votes1100.00% Underperform VotesNo Votes Does the media prefer TRML or CTOR? In the previous week, Tourmaline Bio had 3 more articles in the media than Citius Oncology. MarketBeat recorded 5 mentions for Tourmaline Bio and 2 mentions for Citius Oncology. Tourmaline Bio's average media sentiment score of 0.59 beat Citius Oncology's score of 0.48 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tourmaline Bio 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TRML or CTOR more profitable? Tourmaline Bio's return on equity of -20.97% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% Citius Oncology N/A -43.67%-9.74% Do insiders and institutionals have more ownership in TRML or CTOR? 91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 22.9% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend TRML or CTOR? Tourmaline Bio presently has a consensus price target of $54.00, indicating a potential upside of 342.26%. Citius Oncology has a consensus price target of $3.00, indicating a potential upside of 156.41%. Given Tourmaline Bio's higher possible upside, equities analysts clearly believe Tourmaline Bio is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTourmaline Bio beats Citius Oncology on 8 of the 11 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.86M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / SalesN/A311.27456.6780.61Price / CashN/A67.8344.0437.47Price / Book-5.326.747.634.64Net Income-$21.15M$138.11M$3.18B$245.69M7 Day Performance-6.40%-2.43%-1.91%-2.66%1 Month Performance-11.36%-1.91%-0.19%-2.15%1 Year PerformanceN/A-5.03%16.70%12.90% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius OncologyN/A$1.17-2.5%$3.00+156.4%N/A$85.86MN/A0.00N/AEarnings ReportNews CoverageTRMLTourmaline Bio1.7574 of 5 stars$13.83+5.7%$54.00+290.5%-66.2%$354.60MN/A-4.9044MBXMBX Biosciences2.59 of 5 stars$10.41+15.8%$37.25+257.8%N/A$347.90MN/A0.0036Insider TradeNews CoverageACBAurora Cannabis0.5175 of 5 stars$6.31-4.7%N/A+73.2%$346.17M$200.35M126.231,073Gap UpTERNTerns Pharmaceuticals4.3932 of 5 stars$4.06-0.5%$18.30+350.7%-50.4%$344.86MN/A-3.4440FHTXFoghorn Therapeutics2.7039 of 5 stars$6.13-0.5%$13.17+114.8%-12.4%$340.89M$34.15M-3.19120Positive NewsTSHATaysha Gene Therapies2.5091 of 5 stars$1.63+0.6%$6.63+306.4%-36.1%$334.05M$15.45M2.59180CYRXCryoport2.5802 of 5 stars$6.73+0.4%$12.29+82.6%-61.4%$332.66M$233.26M-1.991,170Positive NewsANNXAnnexon2.5512 of 5 stars$3.07+2.0%$15.80+414.7%-42.8%$327.23MN/A-2.9260News CoverageGap UpCRVSCorvus Pharmaceuticals1.9049 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.59MN/A-5.2530News CoverageTRVITrevi Therapeutics2.7567 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Tourmaline Bio Competitors MBX Biosciences Competitors Aurora Cannabis Competitors Terns Pharmaceuticals Competitors Foghorn Therapeutics Competitors Taysha Gene Therapies Competitors Cryoport Competitors Annexon Competitors Corvus Pharmaceuticals Competitors Trevi Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTOR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts